Prime Therapeutics, June 2025: analysis of 16.5 million covered lives.
The most effective obesity drugs ever developed have a retention problem.
GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are the most important obesity treatment in decades. In clinical trials, patients lost 15–20% of their body weight. For millions of people, these drugs delivered what no diet, exercise program, or previous medication ever could.
This is not an article about whether GLP-1 drugs work. They work.
This is about what happens next.
What a typical GLP-1 patient’s weight trajectory actually looks like, including what happens after they stop.
The green line is the promise. The red line is the reality for the vast majority. Of patients who start GLP-1 therapy for obesity, 47–65% discontinue within the first year alone. JAMA Network Open, Jan 2025, n=125,474
By year three, only 8.1% are still taking their medication, meaning 91.9% have stopped. Prime Therapeutics, Jun 2025, n=16.5M covered lives
The reasons 92% of patients discontinue GLP-1 therapy, from an analysis of 78,781 patients.
After stopping GLP-1 medication, weight regain is 4× faster than after behavioral interventions, regardless of how much weight was initially lost.
GLP-1 therapy is designed to be taken indefinitely. Select a pricing tier to see what that means over time.
And if you’re in the 92% who stop, you’ll regain the weight within 1.7 years.
Weight loss curve based on STEP 1 trial data (semaglutide 2.4 mg). Regain rate: 0.8 kg/month for semaglutide/tirzepatide (BMJ, West et al., Jan 2026). This is a population-level projection, not individual medical advice.